Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530027, P. R. China.
Guangxi Medical University, Nanning, Guangxi, 530021, P. R. China.
Sci Rep. 2017 Jul 25;7(1):6385. doi: 10.1038/s41598-017-06705-y.
Several previously published trials comparing Zotarolimus Eluting Stents (ZES) with Sirolimus Eluting Stents (SES), Paclitaxel Eluting Stents (PES) or Everolimus Eluting Stents (EES) at a follow up period of 1 year, were continually being followed up in order to assess the long-term outcomes. In this meta-analysis, we aimed to compare the long-term (2-5 years) adverse clinical outcomes which were associated with ZES versus SES, PES and EES following Percutaneous Coronary Intervention (PCI). Risk Ratios (RR) with 95% Confidence Intervals (CIs) were generated and the analysis was carried out by the RevMan 5.3 software. In this analysis with a total number of 17,606 participants, ZES and EES were associated with similar adverse outcomes including Stent Thrombosis (ST), myocardial infarction (MI), major adverse cardiac events and repeated revascularization. When ZES were compared with SES and PES during the long-term, MI and definite or probable ST were significantly lower with ZES, with RR: 1.35, 95% CI: 1.17-1.56; P = 0.0001 and RR: 1.91, 95% CI: 1.33-2.75; P = 0.0004 respectively whereas the other adverse outcomes were similarly manifested. Future research should be able to confirm this hypothesis.
几项比较佐他莫司洗脱支架（ZES）与西罗莫司洗脱支架（SES）、紫杉醇洗脱支架（PES）或依维莫司洗脱支架（EES）在 1 年随访期的已发表试验，一直持续进行，以评估长期结果。在这项荟萃分析中，我们旨在比较经皮冠状动脉介入治疗（PCI）后 ZES 与 SES、PES 和 EES 相关的长期（2-5 年）不良临床结局。使用 RevMan 5.3 软件生成风险比（RR）和 95%置信区间（CI），并进行分析。在这项总计 17606 名参与者的分析中，ZES 和 EES 与支架血栓形成（ST）、心肌梗死（MI）、主要不良心脏事件和再次血运重建等不良结局相关。在长期随访中，将 ZES 与 SES 和 PES 进行比较时，ZES 组的 MI 和明确或可能 ST 显著降低，RR：1.35，95%CI：1.17-1.56；P=0.0001 和 RR：1.91，95%CI：1.33-2.75；P=0.0004，而其他不良结局也表现相似。未来的研究应该能够证实这一假设。
